4.7 Article

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial

期刊

EUROPEAN JOURNAL OF CANCER
卷 45, 期 7, 页码 1201-1208

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2009.01.004

关键词

Breast cancer; Gene expression signatures; Logistics; Feasibility study

类别

资金

  1. Cancer Research UK [7714] Funding Source: researchfish
  2. Cancer Research UK [7714] Funding Source: Medline

向作者/读者索取更多资源

Purpose: The 70-gene prognosis-signature is a prognostic tool for early breast cancer analysis. in addition to scientific evidence, implementation of the signature in clinical trials and daily practice requires logistical feasibility. The aim of our study was to test logistics for gene expression profiling on fresh frozen tumour tissue in the preparation for the prospective, multinational Microarray in Node-negative Disease may Avoid Chemo-Therapy (MIN-DACT) trial. Methods: Sixty-four patients were included in six European hospitals. Fresh frozen tumour samples were shipped on dry ice to Agendia B.V., where RNA was isolated and subsequently hybridised on the 70-gene prognosis-signature (MammaPrint(TM)). Results: Tumour samples were obtained in 60 of 64 patients. Among the 60 samples, 11 contained insufficient turnout cells (<50%) and three contained insufficient RNA quality. All 46 samples eligible for genomic profiling were successfully hybridised, and the results were reported on average within 4-5 d. Conclusion: Gene expression profiling on fresh frozen tissue is feasible in daily clinical practice. (C) 2009 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据